Advisors Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Advisors Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,441	Closed	-$160K	–	1455
2025 Q4	$160K	Sell	7,441 -227	-3%	-$4.41K	﹤0.01%	1157
2025 Q3	$117K	Sell	7,668 -25	-0.3%	-$325	﹤0.01%	1200
2025 Q2	$68.1K	Hold	7,693	–	–	﹤0.01%	1253
2025 Q1	$60.2K	Sell	7,693 -44	-0.6%	-$368	﹤0.01%	1266
2024 Q4	$81.3K	Sell	7,737 -184	-2%	-$2.23K	﹤0.01%	1259
2024 Q3	$104K	Buy	7,921 +2,846	+56%	+$43.4K	﹤0.01%	1220
2024 Q2	$71.4K	Buy	+5,075	New	+$82.7K	﹤0.01%	1243

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Advisors Asset Management's AVDL Position: Q1 2026 in Review

Advisors Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 7,441 shares — an estimated $160K sold.

Advisors Asset Management first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $160K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Advisors Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Advisors Asset Management sold 7,441 Avadel Pharmaceuticals shares in Q1 2026, an estimated $160K.
Advisors Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
Advisors Asset Management's Avadel Pharmaceuticals position peaked at $160K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.